咖啡与心力衰竭之间的关联:英国生物银行的一项前性队列研究
Qiang Han1, Jiadong Chu1, Wei Hu1
1Department of Epidemiology and Biostatistics, School of Public Health, Medical College of Soochow University, Suzhou, 215123, China.
Nutrition, metabolism, and cardiovascular diseases : NMCD
|August 10, 2023
概括
适度饮用咖啡可能会降低心力衰竭的风险. 然而,非常高的摄入量可能会增加风险,尽管这种影响在某些群体中可能并不显著.
科学领域:
- 心血管流行病学心血管流行病学
- 营养科学 营养科学
- 公共卫生 公共卫生
背景情况:
- 咖啡摄入量与心力衰竭 (HF) 发生率之间的关联仍然不清楚.
- 现有的研究还没有完全解决随时间变化的咖啡消费模式.
- 本研究探讨了动态咖啡消费与新发性HF之间的联系.
研究的目的:
- 检查时间变化的咖啡消费与发生心力衰竭之间的关系.
- 为了澄清咖啡摄入量与HF风险之间的剂量反应关系.
- 探索性别和吸烟等因素的潜在修饰效应.
主要方法:
- 利用了来自497,503名成年人的英国生物库数据,在基线时没有高射线.
- 采用边际结构模型 (MSM) 来处理时间变化的混因素和跟踪损失.
- 应用受限制的立方线来评估咖啡消费和HF风险之间的非线性关系.
主要成果:
- 在咖啡消费和HF风险之间观察到J形的非线性关联 (P < 0.001).
- 每天摄入1-4杯咖啡与降低HF风险有关,相比之下,每天摄入不到1杯咖啡.
- >6杯/天与HF风险增加有关,但这在性别或吸烟状况的敏感性分析中没有显著意义.
- 咖啡类型显著影响了HF发病率 (P < 0.05).
结论:
- 适度饮用咖啡 (每天1-4杯) 可能与心力衰竭发病率降低的风险有关.
- 在某些子组中,高咖啡消费 (每天超过6杯) 可能不会显著增加HF风险.
- 咖啡的种类是HF发病率的一个重要因素.
相关概念视频
01:27Heart Failure I: Introduction
16
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
16
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:30Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure III: Clinical Manifestations
23
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463